(Q46764337)

English

A phase I study with oral SU5416 in patients with advanced solid tumors: a drug inducing its clearance

scientific article published in July 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16237511

A phase I study with oral SU5416 in patients with advanced solid tumors: a drug inducing its clearance (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16237511

author name string

Marc Salzberg

1

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16237511

Miklos Pless

2

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16237511

Christoph Rochlitz

3

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16237511

Klara Ambrus

4

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16237511

Paul Scigalla

5

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16237511

Richard Herrmann

6

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16237511

publication date

1 July 2006

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16237511

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16237511

24

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16237511

4

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16237511

299-304

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16237511

https://scigraph.springernature.com/pub.10.1007/s10637-005-4061-z

0 references

Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/16237511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16237511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting vascular endothelial growth factor in colorectal cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16237511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16237511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biotransformation of the anti-angiogenic compound SU5416.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16237511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function

1 reference

https://pubmed.ncbi.nlm.nih.gov/16237511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16237511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types

1 reference

https://pubmed.ncbi.nlm.nih.gov/16237511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16237511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16237511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-005-4061-Z

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16237511

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16237511

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46764337&oldid=2130307958"